Triaryl pyrazoline compound inhibits flavivirus RNA replication

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 4, 2006, Pages 1320-1329

  Puig Basagoiti, Francesc ^a   Tilgner, Mark ^a   Forshey, Brett M ^a   Philpott, Sean M ^a,b   Espina, Noel G ^a   Wentworth, David E ^a,b   Goebel, Scott J ^a   Masters, Paul S ^a,b   Falgout, Barry ^c   Ren, Ping ^a   Ferguson, David M ^d   Shi, Pei Yong ^a,b  

^a WADSWORTH CENTER   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[5 (4 CHLOROPHENYL) 3 THIOPHEN 2 YL 4,5 DIHYDROPYRAZOL 1 YL]METHANONE; ANTIVIRUS AGENT; KANAMYCIN KINASE; LUCIFERASE; PYRAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DENGUE VIRUS; DRUG CYTOTOXICITY; DRUG MECHANISM; FLAVIVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; ORTHOMYXOVIRUS; PRIORITY JOURNAL; REPLICON; RNA REPLICATION; RNA SYNTHESIS; RNA TRANSLATION; ST LOUIS FLAVIVIRUS; VIRION; VIRUS ASSEMBLY; VIRUS INFECTION; VIRUS INHIBITION; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; FLAVIVIRUS; PYRAZOLES; RNA, VIRAL; VERO CELLS; VIRUS REPLICATION; WEST NILE VIRUS;

EID: 33645783973     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.4.1320-1329.2006     Document Type: Article

References (56)

1. Adelman, Z. N., I. Sanchez-Vargas, E. A. Travanty, J. O. Carlson, B. J. Beaty, C. D. Blair, and K. E. Olson. 2002. RNA silencing of dengue virus type 2 replication in transformed C6/36 mosquito cells transcribing an inverted-repeat RNA derived from the virus genome. J. Virol. 76:12925-12933.
2. Alvarez, D. E., A. L. De Lella Ezcurra, S. Fucito, and A. V. Gamarnik. 2005. Role of RNA structures present at the 3′UTR of dengue virus on translation, RNA synthesis, and viral replication. Virology 339:200-212.
3. Borowski, P., M. Lang, A. Haag, H. Schmitz, J. Choe, H.-M. Chen, and R. S. Hosmane. 2002. Characterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme. Antimicrob. Agents Chemother. 46:1231-1239.
4. Brandriss, M. W., J. J. Schlesinger, E. E. Walsh, and M. Briselli. 1986. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Virol. 67:229-234.
5. Burke, D. S., and T. P. Monath. 2001. Flaviviruses, p. 1043-1126. In D. M. Knipe and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott William & Wilkins, Philadelphia, Pa.
6. Centers for Disease Control and Prevention. 2002. Provisional surveillance summary of the West Nile virus epidemic-United States, January-November 2002. Morb. Mortal. Wkly. Rep. 51:1129-1133.
7. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
8. Courageot, M.-P., M.-P. Frenkiel, C. D. Dos Santos, V. Deubel, and P. Desprès. 2000. α-Glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum. J. Virol. 74:564-572.
9. Crance, J. M., N. Scaramozzino, A. Jouan, and D. Garin. 2003. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antivir. Res. 58:73-79.
10. Crotty, S., C. E. Cameron, and R. Andino. 2001. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA 98:6895-6900.
11. Deas, T. S., I. Binduga-Gajewska, M. Tilgner, P. Ren, D. A. Stein, H. M. Moulton, P. L. Iversen, E. B. Kauffman, L. D. Kramer, and P.-Y. Shi. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 4599-4609.
12. Diamond, M. S., M. Zachariah, and E. Harris. 2002. Mycophenolic acid inhibits dengue virus infection by preventing replication of viral RNA. Virology 304:211-221.
13. Egloff, M. P., D. Benarroch, B. Selisko, J. L. Romette, and B. Canard. 2002. An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J. 21:2757-2768.
14. Falgout, B., R. H. Miller, and C. J. Lai. 1993. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J. Virol. 67:2034-2042.
15. Goodell, J. R., F. Puig-Basagoiti, B. M. Forshey, P.-Y. Shi, and D. M. Ferguson. Identification of compounds with anti-West Nile virus activity. J. Med. Chem., in press.
16. Guo, J.-T., J. Hayasbi, and C. Seeger. 2005. West Nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79:1343-1350.
17. Hong, Z., and C. E. Cameron. 2002. Pleiotropic mechanisms of ribavirin antiviral activities. Prog. Drug Res. 59:41-69.
18. Horscroft, N., D. Bellows, I. Ansari, V. C. Lai, S. Dempsey, D. Liang, R. Donis, W. Zhong, and Z. Hong. 2005. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response. J. Virol. 79:2788-2796.
19. Hurst, K., L. Kuo, C. Koetzner, R. Ye, B. Hsue, and P. Masters. 2005. A major determinant for membrane protein interaction localizes to the carboxy-terminal domain of the mouse coronavirus nucleocapsid protein. J. Virol. 79:13285-13297.
20. Kimura-Kuroda, J., and K. Yasui. 1988. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 141:3606-3610.
21. Kinney, R., C. Huang, B. Rose, A. Kroeker, T. Dreher, P. Iversen, and D. Stein. 2005. Inhibition of dengue virus serotypes 1 to 4 in Vero cell cultures with morpholino oligomers. J. Virol. 79:5116-5128.
22. Koonin, E. V. 1993. Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus. J. Gen. Virol. 74:733-740.
23. Kuhn, R. J., W. Zhang, M. G. Rossmann, S. V. Pletnev, J. Corver, E. Lenches, C. T. Jones, S. Mukhopadhyay, P. R. Chipman, E. G. Strauss, T. S. Baker, and J. H. Strauss. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
24. Kummerer, B. M., and C. M. Rice. 2002. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J. Virol. 76:4773-4784.
25. Leung, D., K. Schroder, H. White, N.-X. Fang, M. J. Stoermer, G. Abbenante, J. L. Martin, P. R. Young, and D. P. Fairlie. 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem. 276:45762-45771.
26. Leyssen, P., J. Balzarini, E. De Clercq, and J. Neyts. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79:1943-1947.
27. Liu, W., X. J. Wang, V. V. Mokhonov, P.-Y. Shi, R. Randall, and A. A. Khromykh. 2005. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstractural proteins. J. Virol. 79:1934-1942.
28. Liu, W. J., H. B. Chen, and A. A. Khromykh. 2003. Molecular and functional analyses of Kůnjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication. J. Virol. 77:7804-7813.
29. Lo, M. K., M. Tilgner, K. A. Bernard, and P.-Y. Shi. 2003. Functional analysis of mosquito-borne flavivirus conserved sequence elements within 3′ untranslated region of West Nile virus using a reporting replicon that differentiates between viral translation and RNA replication. J. Virol. 77:10004-10014.
30. Lo, M. K., M. Tilgner, and P.-Y. Shi. 2003. Potential high-throughput assay for screening inhibitors of West Nile virus replication. J. Virol. 77:12901-12906.
31. Mathews, J. H., and J. T. Roehrig. 1984. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J. Immunol. 132:1533-1537.
32. McCown, M., M. S. Diamond, and A. Pekosz. 2003. The utility of siRNA transcripts produced by RNA polymerase I in down regulating viral gene expression and replication of negative- and positive-strand RNA viruses. Virology 313:514-524.
33. Migliaccio, G., J. E. Tomassini, S. S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M. R. Bosserman, A. Ceccacci, L. F. Colwell, R. Cortese, R. De Francesco, A. B. Eldrup, K. L. Getty, X. S. Hou, R. L. LaFemina, S. W. Ludmerer, M. MacCoss, D. R. McMasters, M. W. Stahlhut, D. B. Olsen, D. J. Hazuda, and O. A. Flores. 2003. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278:49164-49170.
34. Morrey, J., D. Smee, R. Sidwell, and C. Tseng. 2002. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antivir. Res. 55:107-116.
35. Munoz-Jordan, J. L., G. G. Sanchez-Burgos, M. Laurent-Rolle, and A. Garcia-Sastre. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA 100:14333-14338.
36. Neumann, G., T. Watanabe, H. Ito, S. Watanabe, H. Goto, P. Gao, M. Hughes, D. R. Perez, R. Donis, E. Hoffmann, G. Hobom, and Y. Kawaoka. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 96:9345-9350.
37. Oliphant, T., M. Engle, G. E. Nybakken, C. Doane, S. Johnson, L. Huang, S. Gorlatov, E. Mehlhop, A. Marri, K. M. Chung, G. D. Ebel, L. D. Kramer, D. H. Fremont, and M. S. Diamond. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11:522-530.
38. Olsen, D. B., A. B. Eldrup, L. Bartholomew, B. Bhat, M. R. Bosserman, A. Ceccacci, L. F. Colwell, J. F. Fay, O. A. Flores, K. L. Getty, J. A. Grobler, R. L. LaFemina, E. J. Markel, G. Migliaccio, M. Prhavc, M. W. Stahlhut, J. E. Tomassini, M. MacCoss, D. J. Hazuda, and S. S. Carroll. 2004. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48:3944-3953.
39. Puig-Basagoiti, F., T. S. Deas, P. Ren, M. Tilgner, D. M. Ferguson, and P.-Y. Shi. 2005. High-throughput assays using luciferase-expressing replicon, virus-like particle, and full-length virus for West Nile virus drug discovery. Antimicrob. Agents Chemother. 49:4980-4988.
40. Puri, B., S. Polo, C. G. Hayes, and B. Falgout. 2000. Construction of a full length infectious clone for dengue-1 virus Western Pacific,74 strain. Virus Genes. 20:57-63.
41. Roehrig, J. T., L. A. Staudinger, A. R. Hunt, J. H. Mathews, and C. D. Blair. 2001. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann. N. Y. Acad. Sci. 951:286-297.
42. Ryan, M. D., and J. Drew. 1994. Foot-mouth-disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J. 13:928-933.
43. Schlesinger, J. J., M. W. Brandriss, and E. E. Walsh. 1985. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J. Immunol. 135:2805-2809.
44. Shi, P.-Y., M. Tilgner, and M. K. Lo. 2002. Construction and characterization of subgenomic replicons of New York strain of West Nile virus. Virology 296:219-233.
45. Shi, P.-Y., M. Tilgner, M. K. Lo, K. A. Kent, and K. A. Bernard. 2002. Infectious cDNA clone of the epidemic West Nile virus from New York City. J. Virol. 76:5847-5856.
46. Shimoni, Z., M. J. Niven, S. Pitlick, and S. Bulvik. 2001. Treatment of West Nile virus encephalitis with intravenous immunoglobulin. Emerg. Infect. Dis. 7:759.
47. Tan, B. H., J. Fu, R. J. Sugrue, E. H. Yap, Y. C. Chan, and Y. H. Tan. 1996. Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216:317-325.
48. Vodicka, M. A., W. C. Goh, L. I. Wu, M. E. Rogel, S. R. Bartz, V. L. Schweickart, C. J. Raport, and M. Emerman. 1997. Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses. Virology 233:193-198.
49. Wengler, G., and G. Wengler. 1991. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology 184:707-715.
50. Wengler, G., and G. Wengler. 1993. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197:265-273.
51. Whitby, K., T. C. Pierson, B. Geiss, K. Lane, M. Engle, Y. Zhou, R. W. Doms, and M. S. Diamond. 2005. Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J. Virol. 79:8698-8706.
52. World Health Organization. 2002. Dengue and dengue haemorrhagic fever. [Online.] http://www.who.int/mediacentre/factsheets/fs117/en/.
53. World Health Organization. 2002. Immunization, vaccines and biologicals: Japanese encephalitis. [Online.] http://www.who.int/vaccines-disease/diseases/ je.shtml.
54. World Health Organization. 2001. Yellow fever. [Online.] http://www.who.int/mediacentre/factsheets/fs100/en/.
55. Wu, S.-F., C.-J. Lee, C.-L. Liao, R. A. Dwek, N. Zitzmann, and Y.-L. Lin. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76:3596-3604.
56. Zhang, N., H. M. Chen, V. Koch, H. Schmitz, M. Minczuk, P. Stepien, A. I. Fattom, R. B. Naso, K. Kalicharran, P. Borowski, and R. S. Hosmane. 2003. Potent inhibition of NTPase/helicase of the West Nile virus by ring-expanded ("fat") nucleoside analogues. J. Med. Chem. 46:4776-4789.